Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis
Conditions
Interventions
Dupilumab
Auto-injector Device
+1 more
Locations
37
United States
Regeneron Investigational Site
Birmingham, Alabama, United States
Regeneron Investigational Site
Birmingham, Alabama, United States
Regeneron Investigational Site
Fort Smith, Arkansas, United States
Regeneron Investigational Site
Long Beach, California, United States
Regeneron Investigational Site
Los Angeles, California, United States
Regeneron Investigational Site
Murrieta, California, United States
Start Date
February 28, 2017
Primary Completion Date
November 14, 2017
Completion Date
February 12, 2018
Last Updated
August 1, 2018
NCT03409367
NCT05913791
NCT03175354
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions